vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Resolute Holdings Management, Inc.的1.6倍（$183.1M vs $117.7M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -1.5%，领先14.8%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $24.6M）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
AMPH vs RHLD — 直观对比
营收规模更大
AMPH
是对方的1.6倍
$117.7M
净利率更高
AMPH
高出14.8%
-1.5%
自由现金流更多
RHLD
多$164.6M
$24.6M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $117.7M |
| 净利润 | $24.4M | $-1.7M |
| 毛利率 | 46.8% | 55.7% |
| 营业利润率 | 19.4% | 30.2% |
| 净利率 | 13.3% | -1.5% |
| 营收同比 | -1.8% | — |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRHLD
| Q4 25 | $183.1M | $117.7M | ||
| Q3 25 | $191.8M | $120.9M | ||
| Q2 25 | $174.4M | $119.6M | ||
| Q1 25 | $170.5M | $103.9M | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | — | ||
| Q2 24 | $182.4M | — | ||
| Q1 24 | $171.8M | — |
净利润AMPHRHLD
| Q4 25 | $24.4M | $-1.7M | ||
| Q3 25 | $17.4M | $-231.0K | ||
| Q2 25 | $31.0M | $-611.0K | ||
| Q1 25 | $25.3M | $-3.4M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $37.9M | — | ||
| Q1 24 | $43.2M | — |
毛利率AMPHRHLD
| Q4 25 | 46.8% | 55.7% | ||
| Q3 25 | 51.4% | 59.0% | ||
| Q2 25 | 49.6% | 57.5% | ||
| Q1 25 | 50.0% | 52.5% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHRHLD
| Q4 25 | 19.4% | 30.2% | ||
| Q3 25 | 13.2% | 34.3% | ||
| Q2 25 | 24.2% | 34.0% | ||
| Q1 25 | 21.9% | 24.7% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | — |
净利率AMPHRHLD
| Q4 25 | 13.3% | -1.5% | ||
| Q3 25 | 9.0% | -0.2% | ||
| Q2 25 | 17.8% | -0.5% | ||
| Q1 25 | 14.8% | -3.2% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 25.1% | — |
每股收益（稀释后）AMPHRHLD
| Q4 25 | $0.51 | $-0.20 | ||
| Q3 25 | $0.37 | $-0.03 | ||
| Q2 25 | $0.64 | $-0.07 | ||
| Q1 25 | $0.51 | $-0.39 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $205.5M |
| 总债务越低越好 | $608.7M | $169.8M |
| 股东权益账面价值 | $788.8M | $6.5M |
| 总资产 | $1.6B | $333.4M |
| 负债/权益比越低杠杆越低 | 0.77× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资AMPHRHLD
| Q4 25 | $282.8M | $205.5M | ||
| Q3 25 | $276.2M | $148.0M | ||
| Q2 25 | $231.8M | $99.9M | ||
| Q1 25 | $236.9M | $71.0M | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
总债务AMPHRHLD
| Q4 25 | $608.7M | $169.8M | ||
| Q3 25 | $608.6M | $173.4M | ||
| Q2 25 | $607.7M | $177.1M | ||
| Q1 25 | $603.9M | $180.7M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHRHLD
| Q4 25 | $788.8M | $6.5M | ||
| Q3 25 | $776.7M | $10.8M | ||
| Q2 25 | $757.5M | $9.6M | ||
| Q1 25 | $751.3M | $8.9M | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | — | ||
| Q2 24 | $713.3M | — | ||
| Q1 24 | $672.4M | — |
总资产AMPHRHLD
| Q4 25 | $1.6B | $333.4M | ||
| Q3 25 | $1.7B | $293.2M | ||
| Q2 25 | $1.6B | $253.3M | ||
| Q1 25 | $1.6B | $214.3M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
负债/权益比AMPHRHLD
| Q4 25 | 0.77× | 26.03× | ||
| Q3 25 | 0.78× | 16.01× | ||
| Q2 25 | 0.80× | 18.42× | ||
| Q1 25 | 0.80× | 20.38× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $189.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 160.8% |
| 资本支出强度资本支出/营收 | 4.5% | 5.8% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $313.2M |
8季度趋势，按日历期对齐
经营现金流AMPHRHLD
| Q4 25 | $32.9M | $196.1M | ||
| Q3 25 | $52.6M | $59.6M | ||
| Q2 25 | $35.6M | $48.9M | ||
| Q1 25 | $35.1M | $18.4M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | — | ||
| Q2 24 | $69.1M | — | ||
| Q1 24 | $55.3M | — |
自由现金流AMPHRHLD
| Q4 25 | $24.6M | $189.2M | ||
| Q3 25 | $47.2M | $58.6M | ||
| Q2 25 | $25.0M | $47.5M | ||
| Q1 25 | $24.4M | $17.8M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
自由现金流率AMPHRHLD
| Q4 25 | 13.4% | 160.8% | ||
| Q3 25 | 24.6% | 48.5% | ||
| Q2 25 | 14.3% | 39.7% | ||
| Q1 25 | 14.3% | 17.1% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
资本支出强度AMPHRHLD
| Q4 25 | 4.5% | 5.8% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 6.1% | 1.2% | ||
| Q1 25 | 6.3% | 0.6% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
现金转化率AMPHRHLD
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RHLD
暂无分部数据
